

Dear Editor,

We are very appreciated that you are interested in our case.

We have revised the manuscript according to the review report and the comments and answered all of the reviewers' comments carefully.

First of all, we have revised and verified the accuracy of the general information for our manuscript.

Secondly, we have signed the Copyright License Agreement form and uploaded it as attached.

Thirdly, we have update the manuscript according to the Guidelines and Requirements for Manuscript Revision and the Format for Manuscript Revision for 'Case Report'.

Fourthly, we used language editing services provided by American Journal Experts which had a certification as attached. And we edited the English again seriously.

Reviewers' comments:

1. Author wrote legends above figures.

Answer: we have uploaded the figures in the TIFF format as attached and the legend is below each image in the revised manuscript.

2. The limitations of the study is use only one dose of human monoclonal antibodies (pembrolizumab) and then they stope due to fever and infection.

So are sure the finding and clearance of the tumor is due to radiotherapy only or due to continue with one dose of immunotherapy

Answer: As we all known, PSC is a type of tumor which is not sensitive to either radiotherapy or chemotherapy. For this patient, he receive radiotherapy from 12 June to 26 June, totally 1200cGy to relieve chest wall pain, a CT scan between the end of radiotherapy and start of immunotherapy showed tumor progression. And after pembrolizumab, a controlled CT revealed that the tumor shrank obviously. So we think the clearance of the tumor is probably due to immunotherapy or due to the combination of radiotherapy and immunotherapy, but not due to radiotherapy only.

Best Regards,
Shuang Zhang